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Chronic pancreatitis (CP) is a rare condition characterised 
by progressive and irreversible inflammatory changes that 
potentially leads to exocrine and endocrine damage of the 
pancreas. Alcohol abuse is an important cause of CP, but 
other factors such as anatomical changes, metabolic disease 
and autoimmunity are also implicated. On the other hand, 
genetic factors clearly underlie a substantial portion of CP 
cases.1,2 The pace of developments in this field has been 
very rapid, making it appropriate to review some of the key 
advances. Trypsin and trypsin inhibitors are thought to be 
central to the pathogenesis of CP. Trypsinogen is produced in 
the pancreas, secreted into the small intestine, and converted 
to trypsin. Trypsin hydrolyses proteins into smaller peptides 
or amino acids. Premature pancreatic activation of trypsin 
and subsequent pancreatitis is the central concept in CP and 
documented by recent experimentation. The effect of genetics 
is most obvious in a familial form of pancreatitis. Here, CP is 
inherited in an autosomal dominant trait. Patients develop CP 
early, and the clinical profile is similar to that of non-inherited 
CP, but the lifetime risk for pancreatic cancer is very high. 
Mutations in cationic trypsinogen (PRSS1) cause familial 
CP. Two mutations, R122H and N29I, are very common 
and account for almost all familial cases assessed so far.3 
Functional analysis of these mutants demonstrated enhanced 
autoactivation, pointing to a gain of function. This seems to 
support the concept that enhanced intrapancreatic trypsin 
causes pancreatic inflammation and autolysis. A second 
isoform of trypsinogen, anionic trypsinogen (PRSS2) is also 
involved in CP. A recent study showed that one PRSS2 mutant, 
G191R, actually protects against CP, as it was found in 3.4% of 
controls, but in 1.3% of affected individuals.4 It appeared that 
this mutant encoded non-functional trypsinogen, a severe 
loss of function. So far, disease enhancing PRSS2 mutants 
have not been found. The clinical implications are limited, 
though G191R carriers developed the disease at a significant 
later age. 
One of the best-known trypsin inhibitors is serine protease 
inhibitor, Kazal type 1 (SPINK1). It appears that one specific 
mutation (N34S) is enriched in CP patients. Many case control 
studies show that N34S is found mostly in patients without 
a clear underlying cause for CP, as 15-40% of patients with 
so-called idiopathic CP carry N34S on one allele or on both 
alleles.5,6 Though it is logical to assume that N34S decreases the 
inhibitory effect of SPINK1, functional analysis does not show 
any effect. However, N34S is coinherited with other, nearby 
located SPINK1 variants. It is conceivable that these variants 
cause the effect. The last, and most recent development is 
the discovery of trypsin-degrading enzyme chymotrypsin 
C (CTRC) variants. Similar to SPINK1 it inhibits trypsin 
and serves as a protective mechanism against pancreatitis. 
Using a very large European CP cohort it was shown that 
two CTRC mutants were significantly overrepresented in CP 
patients compared to controls (3.5 vs. 0.7%).7 Functional assays 
demonstrated that these mutants reduce CTRC activity and/or 
impair secretion. Again, the results accord with the common 
theme that loss of function of a trypsin inhibitory enzyme 
predisposes to CP, apparently by diminishing its protective 
trypsin degrading activity. All in all, these studies provide 
support for the central role of trypsin in the pathogenesis of 
CP. Without doubt future studies will identify other players in 
this pathway that modify the risk for CP. 
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